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INTRODUCTION 
Autoimmune diseases are characterized by thepresence of auto-antibodies against a wide va-
riety of intracellular auto-antigens; in normal con-
ditions intracellular proteins do not raise the cell
surface, nevertheless under apoptosis or necrosis
the intracellular proteins are translocated to cell
membranes and extra cellular space, therefore the
molecules suffer conformational changes that play
a role in the antigen driven response (1). 
Apoptosis is a physiologic mechanism that pre-
serves the tissue development and protects organ-
isms by removing defective and senescent cells,
the clearance of apoptotic material avoid the “tox-
ic accumulation” (2). Defects in apoptosis could
shut down the tolerance in genetically predisposed
individuals.
A failure of Fas/FasL pathway could allow the sur-
vival of autoimmune lymphocytes which escape
the negative selection into the thymus. Fas defects
have been demonstrated in animal models and hu-
man SLE. In addition, mutations of C3, C1q, Fc re-
ceptors and pentraxines result in a defective recog-
nition and a lack of cleaning of cellular debris
which trigger off autoantibodies (3-9). 
In clinical practice is difficult to define whether
autoantibody response is triggered by native or
cryptic antigens produced under apoptosis or
necrosis. To answer this important question, apop-
tosis or necrosis was chemically induced in HEp-
2 cells and the protein antigenicity was probed with
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Obiettivo. Lo scopo di questo studio è quello di indagare se l’apoptosis e la necrosi aumentano l’antigenicità delle
proteine riconosciute da anticorpi antinucleo. 
Materiale e metodi. Cellule HEp-2 sono state coltivate in condizioni standard; l’apoptosis è stata indotta con camp-
tecina e la necrosi con cloruro di mercurio. L’antigenicità delle proteine estratte dalle cellule è stato testata su mem-
brane di nitrocellulosa e sondata con sieri positivi o negativi per anticorpi antinucleo utilizzando un sistema ELISA
a luminescenza (luminescent). 
Risultati. Le alterazioni apoptotiche nelle cellule HEp-2 sono apparse entro 24 ore dall’esposizione alla camptoici-
na, mentre i segni di necrosi si sono evidenziati più precocemente. La luminescenza si è dimostrata significativamen-
te superiore nei sieri ANA positivi che nei controlli ANA negativi. Gli antcorpi antinucleari sieirici riconoscono me-
glio gli antigeni da cellule apoptotiche e necrotiche rispetto ai controlli che non hanno subito trattamenti chimici.
Conclusioni. L’apoptosi e la necrosi incrementano la capacità legante degli ANA attraverso una migliore disponibi-
lità di antigeni intracellulari o svelando epitopi criptici.
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MATERIAL AND METHODS
Sera. One hundred and sixty two sera were stud-
ied. Eighty one had positive ANA on HEp-2 cells
(titer higher than 1:80). Sera were obtained from
patients with systemic lupus erythematosus (SLE)
n=60, primary Sjögren syndrome (SS) n=5, pro-
gressive systemic sclerosis (SE) n=15 and mixed
connective tissue disease (MCTD) n=1 (10-13).
The remaining eighty one sera were obtained from
negative ANA healthy controls.
Cell cultures. Epithelial HEp-2 cells obtained from
ATTC were grown in DMEM medium supple-
mented with 10% fetal calf serum (Gibco, BRL.
Gaithersburg MD). Cells were suspended and plat-
ed in culture flasks at a density of 5x10
6
/ml and in-
cubated at 37°C 5% CO2 and 85% of relative hu-
midity. Cells in logarithmic growth phase (1X106)
were incubated 24 h with 20 mM camptothecin
(Sigma. St Louis, MO) (14). Another culture was
incubated 24 hours with 5 mM mercuric chloride
to induce necrosis (15). Control cells were cultured
without chemicals. Changes in cell morphology
were determined by light microscopy. Apoptotic
fragments were detected by TUNEL (Roche Diag-
nostics GmbH, Mannheim, Germany). 
Indirect Immunofluorescence. Antinuclear anti-
bodies were tested on HEp-2 cells, the slides were
incubated 30 minutes with serum diluted 1:80 to
1:10,280, followed by PBS washings and 30’ in-
cubation with FITC-labeled rabbit anti-human
polyclonal gamma globulin (IgG, IgA and IgM,
Sigma. St Louis, MO), after washings the slides
were evaluated in epifluorescent microscopy.
Antigen extraction. Cells were harvested with a
scraper and spun at 1200 rpm/10 minutes, then sus-
pended in denaturing lysis buffer (1% SDS, 0.25M
EDTA, 2mM bis-mercaptoethanol, 1mM tris pH
7.5, 5mM PMSF and adjusted to 1 ml H2O). The
soluble antigens were extracted by sonication,
lysates were centrifuged at 12000 rpm/10 minutes
and supernatants used for analysis. Protein con-
centration was measured by spectrophotometer at
280 nm.
Luminescent-spot-ELISA (LsELISA). Cell extracts
adjusted to 2 µg/µl were immobilized onto nitro-
cellulose membranes (BioBlot-NC, Cambridge,
MA) and dried at room temperature, then blocked
with 3% non-fat milk dissolved in PBS. Antigenic
spots were incubated 30 minutes with a 1:3000 di-
lution of serum, membranes were washed in PBS-
0.1% Tween 20 and incubated 30’ with a 1:1000
dilution of goat anti-human polyvalent gamma
globulin (IgG, IgA and IgM) labeled with peroxi-
dase, after washings the luminescent reaction was
developed with ECL (Amersham Pharmacia
Biotech. Piscataway, NJ). Membranes were ana-
lyzed in a Chemi-BioRad image analyzer. The pro-
tein concentration of cell extracts was decided by
an optimization curve taking into account sensitiv-
ity and specificity. 
Preparation of F(ab’)2 fragments. Sera were di-
gested as follows: One hundred ml of serum were
incubated during 22 h at 37°C with 200 ml of
pepsin (Sigma. St Louis, MO), the enzyme was ac-
tivated by 0.1M acetate buffer, pH 3.6 (1 mg/ml).
After incubation the tubes were spun 20’ at 2500
rpm and the supernatant was saved and neutralized
with 0.15M Tris-HCl, pH 8.2 (16). F(ab’)2 frag-
ments were tested by LsELISA as previously de-
scribed.
Statistics. Mean values obtained by the image an-
alyzer were submitted to a multivariate analysis, the
R value of intra and inter-assay was determined by
canonical correlation. The critical comparisons be-
tween positive and negative ANA sera using nor-
mal, apoptotic and necrotic cell extracts was cal-
culated by paired t-Test using the NCSS program. 
RESULTS
Apoptosis and necrosis. Cellular changes were pro-
duced by the chemicals within 24 hours. The apop-
totic cells showed: blebs, apoptotic bodies and
chromatin fragmentation, therefore the ~98% of
cells incubated with camptothecin exhibited posi-
tive TUNEL, meanwhile the percent of cells incu-
bated without it was <1%. The mercuric chloride
induced necrotic changes in the ~99% of cells with-
in 12 hours incubation (Figure 1 and 2).
Recognition of HEp-2 cell antigens. Positive ANA
serum recognized the antigens from normal control
cells; in sharp contrast the ANA negative controls
did not recognize the HEp-2 cell antigens (p
<0.0001). Table I and figure 3. Results of this as-
say were reproducible; therefore the intra-assay
and inter-assay correlation showed a significant R
value (1.00), in five replicas.
Figure 2 - TUNEL in HEp-2 cells. A Control cells negative for TUNEL
(green), the nuclei of living cells are rather stained in red by the 0.2%
propidium iodide. B. Cells incubated 24 hours with camptothecin are
tagged in green by the TUNEL reagent, all the cells are death. 
Apoptosis and necrosis enhance antigenicity. The
ANA reactivity was significantly higher using
apoptotic and necrotic cell extracts than those val-
ues obtained with the control cell extracts (p
<0.0001). In addition, no differences were found in
positive ANA sera using apoptotic and necrotic cell
extracts (Table I, Figure 3). 
HEp-2 cell antigens recognition by F(ab’)2. To rule
out the non-specific binding of the serum to cell
antigens the following experiments were carried
out: 
1) The influence of the complement was ruled out
pre-heating the serum at 56°C for 30 minutes;
under this approach the luminescent values did
not show significant variations. 
2) To assess the influence of self Fc interaction, the
sera were digested with pepsin to obtain F(ab’)2
fragments. The LsELISA values of F(ab’)2 frag-
ments were similar to those of total serum in
presence of anti-F(ab’)2 as second antibody;
nevertheless they were negative with anti-Fc as
second antibody (Table II). 
3) To demonstrate the antigenic specificity, the
membranes were coated with 3% bovine serum
albumin, and the positive and negative ANA
sera were tested; under this condition sera did
not reacted. 
Not differences of ANA reactivity between sub-
groups of patients (SLE, SE, SS, and MCTD) were
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Figure 1 - A representative
panel of HEp-2 cells cultu-
red and evaluated under li-
ght microscopy. Living cel-
ls (left); apoptotic cells
(middle) showing blebs and
apoptotic bodies (arrows);
necrotic cells (right)
showing cell disruption. 
Table I - Statistical data of LsELISA units in 162 sera (n=81 +ANA, 
81 -ANA.
Sera/Antigen Mean/sd Variable P value
A +ANA/Living cells 753±31.8 A vs. C, E < 0.0001
B -ANA/Living cells 1.04±0.70 A vs. B < 0.0001 
C +ANA/Apoptosis 1684±93 C vs. E 0.2624
D -ANA/Apoptosis 1.04 ± 0.59 C vs. D < 0.0001
E +ANA/Necrosis 1532±98 E vs. F < 0.0001
F -ANA/Necrosis 1.04± 0.46 F vs. D, B 1.0000 
P < 0.05 means significant different by paired t Test
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Table II - Statistical data of LsELISA units in 81 +ANA sera heated or digested.
Sera/Antigen Mean/sd Variable P value
A ANA sera/Control cells 753±31.8 A vs. B 0.5023
B ANA sera/56°C/Control cells 722±32.1 B vs. C 0.4676
C ANA F(ab’)2/Control cells/Anti-F(ab’)2 740±32.1 A vs. C 0.4239
D ANA F(ab’)2/Control cells/Anti-Fc 0.006±0.002 D vs C P<0.0001
E ANA sera/Apototic cells 1684±93 E vs. F 0.9845
F ANA sera/56°C/Apoptotic cells 1682±92 F vs. G 0.8778
G ANA F(ab’)2/Apoptotic cells/Anti-F(ab’)2 1702±90 G vs. E 0.8939
H ANA F(ab’)2/Apoptotic cells/Anti-Fc 0.001±0.009 H vs. G P<0.0001
I ANA sera/Necrotic cells 1532±98 I vs. J 0.9936
J ANA sera/56°C/Necrotic cells 1533±97 J vs. K 0.9869
K ANA F(ab’)2/Necrotic cells/Anti-F(ab’)2 1536±97 K vs. I 0.9806
L ANA F(ab’)2/Necrotic cells/Anti-Fc 0.004±0.003 K vs L P<0.0001
P < 0.05 means significant different by paired t Test
Figure 3 - LsELISA. The pa-
nels show the ANA reacti-
vity images of the control,
apoptotic and necrotic cell
extracts probed with negati-
ve and positive ANA sera. 
observed, using normal, apoptotic or necrotic cell
extracts.
DISCUSSION
In this study we showed that the antigenic proper-
ties of molecules recognized by antinuclear anti-
bodies was appraised using apoptotic or necrotic
cell extracts, the main results were the following: 
1) Positive ANA sera specifically recognize au-
toantigens from HEp-2 cells by LsELISA. 
2) Normal human sera did not recognize the HEp-
2 cell antigens. 
3) The ANA binding to cell extracts was increased
in antigens produced by apoptosis or necrosis. 
Apoptosis is a physiologic condition triggered by
internal or external conditions; after apoptosis the
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cellular material is removed by a number of con-
served mechanisms that involve the recognition,
phagocytosis and degradation of the cellular re-
mains. A failure in the apoptotic material clear-
ance would produce toxic accumulation, which
stimulate an antigen driven response (17). Au-
toantigens are cleaved by apoptosis and/or necro-
sis, and then intracellular molecules raise the cell
membrane or the extra-cellular space becoming ac-
cessible to the antigen presenting cells (18-22).
Pioneer observations demonstrated that treatments
with procainamide, hydralazine or other drugs may
lead to ANA production, this suggested that au-
toimmunity would be chemically induced (23).
Chemotherapy in cancer induces autoantibodies;
for example the camptothecin increases the DNA
topoisomerase I levels leading anti-nucleolar or an-
ti-La autoantibodies (24, 25). In addition the in-
toxication with heavy metals as the mercuric chlo-
ride produces anti-nucleolar antibodies (26). In
summary, the tolerance would be braked down by
chemicals and others factors; however in clinical
practice it is difficult to determine who drives the
autoantibody production. 
With the notion that autoantibodies are hallmarks
and fingerprints of autoimmunity (27), ANA sera
were used to explore whether apoptosis or necro-
sis were involved in the antigen driven response in
autoimmune patients. Present results suggest that
cryptic antigens produced under experimental
apoptosis or necrosis react better to ANA than the
native antigens; this result is coincident with oth-
ers who had shown that apoptosis increases the
HEp-2 cell antigenicity (28).
The apoptosis induces antigen redistribution on cell
membrane, by this process the intracellular mole-
cules are exposed by the membrane polarity shift;
therefore the loss of phospholipids asymmetry al-
lows the interaction between the membrane phos-
pholipids with chromatin, ribonucleoproteins and
other intracellular molecules via phosphatidylser-
ine (29, 30). In addition, the protein cleavage would
release neo-antigens which potentially increase the
ANA reactivity (31, 32). By these results we would
like to suggest that the apoptosis and necrosis are
involved in the antigen driven response of antinu-
clear antibodies. 
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SUMMARY
Objective. Present study addresses the issue whether apoptosis and necrosis increases the antigenicity of proteins rec-
ognized by antinuclear antibodies.
Material and methods. HEp-2 cells were cultured in standard conditions; apoptosis was induced by camptothecin and
necrosis by mercuric chloride. Protein antigenicity of cell extracts was tested onto nitrocellulose membranes and
probed with positive or negative sera for antinuclear antibodies by a luminescent-dot-ELISA system.
Results. Apoptotic changes in HEp-2 cells appeared by 24 hours of camptothecin exposure, meanwhile the necrotic
features become visible earlier. Luminescence was significantly superior in ANA positive sera than in ANA negative
controls. Antinuclear antibody sera recognized better the antigens from the apoptotic and necrotic cells than controls
without chemical treatments. 
Conclusions. Apoptosis and necrosis increase the ANA binding by better availability of intracellular antigens, or by
disclosing cryptic epitopes.
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